CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $207.51M, lower than 95% of all stocks globally
- PositionCurrent ratio is 1.31×, lower than 95% of its Medical Devices peers (median 3.83×)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
293.07BKRW207.51M · vs all stocks (USD)
Revenue (TTM)
124.81BKRW88.37M · vs all stocks (USD)
Profit Margin
-15.75%vs Medical Devices peers
Beta
1.97xvs all stocks
52-Week Change
146.57%vs all stocks
Market Capitalization
293.07BKRW207.51M · vs all stocks (USD)
Enterprise Value
323.39BKRW228.97M · vs all stocks (USD)
Forward P/E
10.67xvs Medical Devices peers
Price to Sales (TTM)
2.41xvs Medical Devices peers
Price to Book (MRQ)
3.67xvs Medical Devices peers
Enterprise to Revenue
2.59xvs Medical Devices peers
Enterprise to EBITDA
-23.46xvs Medical Devices peers
Gross Margin
62.58%vs Medical Devices peers
Profit Margin
-15.75%vs Medical Devices peers
Operating Margin
11.27%vs Medical Devices peers
Return on Assets (TTM)
-8.15%vs Medical Devices peers
Return on Equity (TTM)
-29.22%vs Medical Devices peers
Revenue (TTM)
124.81BKRW88.37M · vs all stocks (USD)
Revenue per Share (TTM)
9.09KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
65.00%vs Medical Devices peers
Gross Profit (TTM)
74.65BKRW52.85M · vs all stocks (USD)
EBITDA (TTM)
-13.78BKRW-9.76M · vs all stocks (USD)
Net Income (TTM)
-19.66BKRW-13.92M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
42.77%vs Medical Devices peers
Operating Cash Flow (TTM)
-15.64BKRW-11.07M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-16.94BKRW-11.99M · vs all stocks (USD)
5-Year Average Dividend Yield
0.50%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
182.70MKRWFY2025 · Sep 30, 2025Revenue
89.78BKRWFY2025 · Sep 30, 2025Cost of Goods Sold
38.27BKRWFY2025 · Sep 30, 2025Gross Profit
51.51BKRWFY2025 · Sep 30, 2025Operating Income
-25.89BKRW-18.33M · vs all stocks (USD)
Pre-tax Income
-29.75BKRWFY2025 · Sep 30, 2025Income Tax Expense
2.32BKRWFY2025 · Sep 30, 2025Net Income
-32.08BKRWFY2025 · Sep 30, 2025EBIT
-27.92BKRWFY2025 · Sep 30, 2025EBITDA (Income Statement)
-20.82BKRWFY2025 · Sep 30, 2025Research & Development
5.37BKRWFY2025 · Sep 30, 2025Selling, General & Administrative
51.61BKRWFY2025 · Sep 30, 2025Other Operating Expenses
863.50MKRWFY2025 · Sep 30, 2025Non-operating Interest Income
108.67MKRWFY2025 · Sep 30, 2025Non-operating Interest Expense
1.83BKRWFY2025 · Sep 30, 2025EPS (Basic)
-2.41KKRWFY2025 · Sep 30, 2025EPS (Diluted)
-2.41KKRWFY2025 · Sep 30, 2025Basic Shares Outstanding
12.99MSharesFY2025 · Sep 30, 2025Diluted Shares Outstanding
12.99MSharesFY2025 · Sep 30, 2025Net Income from Continuing Operations
-32.08BKRWFY2025 · Sep 30, 2025Minority Interests (P&L)
733.77MKRWFY2025 · Sep 30, 2025Operating Cash Flow
-14.52BKRWFY2025 · Sep 30, 2025Free Cash Flow
-16.11BKRWFY2025 · Sep 30, 2025Cash & Cash Equivalents (End of Period)
8.15BKRWFY2025 · Sep 30, 2025Starting Profit (CF Statement)
-32.08BKRWFY2025 · Sep 30, 2025Stock-based Compensation
21.09MKRWFY2025 · Sep 30, 2025Other Non-cash Items
24.58BKRWFY2025 · Sep 30, 2025Change in Accounts Receivable (CF)
-7.11BKRWFY2025 · Sep 30, 2025Change in Other Assets/Liabilities
60.99MKRWFY2025 · Sep 30, 2025Capital Expenditures
-1.59BKRWFY2025 · Sep 30, 2025Net Intangibles (CF)
-57.18MKRWFY2025 · Sep 30, 2025Net Acquisitions
-1.50BKRWFY2025 · Sep 30, 2025Purchase of Investments
-20.00MKRWFY2025 · Sep 30, 2025Other Investing Activity
107.82MKRWFY2025 · Sep 30, 2025Net Investing Cash Flow
-3.01BKRWFY2025 · Sep 30, 2025Long-term Debt Issuance
7.00BKRWFY2025 · Sep 30, 2025Other Financing Charges
-10.00KRWFY2025 · Sep 30, 2025Net Financing Cash Flow
7.00BKRWFY2025 · Sep 30, 2025Shares Outstanding
14.26MSharesUpdated Aug 19, 2026Float Shares
9.27MSharesUpdated Aug 19, 2026% Held by Insiders
39.16%vs all stocks
% Held by Institutions
11.14%vs all stocks
Total Cash (MRQ)
19.62BKRW13.89M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.37KKRWUpdated Aug 19, 2026Total Debt (MRQ)
42.14BKRW29.84M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5403xvs Medical Devices peers
Current Ratio (MRQ)
1.30xvs Medical Devices peers
Book Value per Share (MRQ)
5.19KKRWUpdated Aug 19, 2026Total Assets
126.41BKRW89.50M · vs all stocks (USD)
Total Current Assets
56.07BKRWFY2025 · Sep 30, 2025Total Liabilities
92.52BKRWFY2025 · Sep 30, 2025Total Non-current Assets
70.34BKRWFY2025 · Sep 30, 2025Total Non-current Liabilities
11.49BKRWFY2025 · Sep 30, 2025Total Current Liabilities
81.03BKRWFY2025 · Sep 30, 2025Cash Equivalents
8.15BKRWFY2025 · Sep 30, 2025Cash & Cash Equivalents
8.15BKRWFY2025 · Sep 30, 2025Accounts Receivable
16.65BKRWFY2025 · Sep 30, 2025Inventory
28.83BKRWFY2025 · Sep 30, 2025Accounts Payable
5.40BKRWFY2025 · Sep 30, 2025Short-term Debt
36.11BKRWFY2025 · Sep 30, 2025Other Current Liabilities
1.99BKRWFY2025 · Sep 30, 2025Long-term Debt
7.20BKRWFY2025 · Sep 30, 2025Other Non-current Liabilities
10.00KRWFY2025 · Sep 30, 2025Common Stock (Book)
6.76BKRWFY2025 · Sep 30, 2025Retained Earnings
-46.32BKRWFY2025 · Sep 30, 2025Total Shareholders' Equity
33.89BKRW23.99M · vs all stocks (USD)
Treasury Stock
5.83BKRWFY2025 · Sep 30, 202552-Week Low
6.97KKRWUpdated Aug 19, 202652-Week High
57.80KKRWUpdated Aug 19, 202652-Week Change
146.57%vs all stocks
Beta
1.97xvs all stocks
50-Day MA
22.94KKRWUpdated Aug 19, 2026200-Day MA
31.03KKRWUpdated Aug 19, 2026Avg 10-Day Volume
122.56KSharesUpdated Aug 19, 2026Avg 30-Day Volume
164.71KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-2.41KKRWUpdated Aug 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Decline With Range Expansion And Drawdown
The price is falling, swinging wider than usual, and sits well below its peak.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 1.31×, lower than 95% of its Medical Devices peers (median 3.83×)Significant
Current ratio: 1.30Industry median: 3.83Industry P5: 1.47Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.63Profit Margin: -0.16
Financial Health
Altman Z-Score 1.13: grey zoneSignificant
Altman Z-Score: 1.13
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $207.51M, lower than 95% of all stocks globallySignificant
Market cap (USD): 207,506,055.873Global P5: 269,387,740.27
Companies that share the same coordination system — how they create, deliver, or capture value.
Avidity Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Genomictree Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Keros Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
NextBioMedical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Koa Shoji Holdings Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Humedix Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Coherus Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Minerva Neurosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
ImmuneOncia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Hangzhou XZB Tech Co., Ltd.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Wintao Communications Co.
2 interpretationsDecline With Range Expansion And DrawdownUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated